Tricyclic antidepressants (TCAs) have been reported to interact with the Opioid Receptor system, but their pharmacological activity at opioid receptors has not yet been elucidated.
We would like to share a recent publications that sheds more light on the mystery. Our purified rabbit ployclonal phosphoERK1/2 Antibody is also referenced.
Pierluigi Onali, Simona Dedoni and Maria C. Olianas. Direct Agonist Activity of Tricyclic Antidepressants at Distinct Opioid Receptor Subtypes. JPET January 2010 vol. 332 no. 1 255-265 .
At the cloned μ-opioid receptor, TCAs showed low affinity and no significant agonist activity. These results show that TCAs differentially regulate opioid receptors with a preferential agonist activity on either δ or κ subtypes and suggest that this property may contribute to their therapeutic and/or side effects.
Related Reagents:
phosphoERK1/2 (Rabbit MAb)
Immune Response Research Antibodies
Immune Response Research Proteins
Neurotrophins and Growth Factor Antibdodies
Neurotrophin Proteins
Pain and Inflammation Research Antibodies
Scientists grow retina cells from skin-derived stem cells
-
WASHINGTON - University of Wisconsin-Madison researchers have successfully
grown multiple types of retina cells from two types of stem cells, giving
new ho...
14 years ago
Posts
